ASTRAZENECA PLC
AZN · NYSE · CIK 0000901832
SIC 2834
Pharmaceutical Preparations
Category
Chemicals
Entity
other
Incorp.
X0
Fiscal Y/E
1231
Source: SEC EDGAR · All filings on SEC →
Investment Indicators
$181.86
-0.99 (-0.54%)
Open
$183.79
High
$185.81
Low
$181.73
Prev Close
$182.85
Volume
2,012,059
52W High
$210.50
52W Low
$130.04
50-day MA
$193.82
Quote as of: 2026-05-11
Market Cap
$283.47B
P/E
27.54
P/B
5.99
PEG
1.52
EPS
6.64
BPS
30.56
Dividend Yield
1.75%
Beta
0.22
Financial Statements
No XBRL data — applies to ETFs and some funds📄 SEC Filings
Foreign Current
TOTAL VOTING RIGHTS AND ADMISSION OF SHARES
2026-05-01
Open →
Foreign Current
FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER
2026-05-01
Open →
Foreign Current
FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER
2026-05-01
Open →
Foreign Current
1ST QUARTER RESULTS
2026-04-29
Open →
Foreign Current
BREZTRI APPROVED IN THE US FOR ASTHMA
2026-04-28
Open →
Foreign Current
SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US
2026-04-27
Open →
Foreign Current
DIRECTORATE CHANGE
2026-04-23
Open →
Foreign Current
I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT
2026-04-21
Open →
Foreign Current
THIRD TOZORAKIMAB POSITIVE PHASE III IN COPD
2026-04-20
Open →
Foreign Current
RESULT OF AGM
2026-04-09
Open →
Foreign Current
IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER
2026-04-02
Open →
Foreign Current
TOTAL VOTING RIGHTS AND ADMISSION OF SHARES
2026-04-01
Open →
Foreign Current
EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS
2026-03-31
Open →
Foreign Current
TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS
2026-03-27
Open →
Foreign Current
NOTIFICATION OF ADMISSION OF SHARES
2026-03-20
Open →
Foreign Current
IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER
2026-03-16
Open →
Foreign Current
NOTICE OF AGM
2026-03-10
Open →
Foreign Current
FORM 6-K
2026-03-10
Open →
Foreign Current
DIRECTOR/PDMR SHAREHOLDING
2026-03-06
Open →
Foreign Current
DIRECTOR/PDMR SHAREHOLDING
2026-03-06
Open →
Foreign Current
DIRECTOR/PDMR SHAREHOLDING
2026-03-06
Open →
Foreign Current
FORM 6-K
2026-03-02
Open →
Foreign Current
TOTAL VOTING RIGHTS
2026-03-02
Open →
Foreign Current
ASTRAZENECA PRICES A $2BN BOND OFFERING
2026-02-26
Open →
Foreign Current
FILING OF FORM 20-F WITH SEC
2026-02-25
Open →
Foreign Annual
20-F
2026-02-24
Open →
Foreign Current
FORM 6-K
2026-02-24
Open →
Foreign Current
ANNUAL FINANCIAL REPORT
2026-02-24
Open →
Foreign Current
DIRECTORATE CHANGE
2026-02-24
Open →
Foreign Current
FIXED-DURATION CALQUENCE COMBO APPROVED IN US
2026-02-20
Open →
Foreign Current
FINAL RESULTS
2026-02-10
Open →
Foreign Current
UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION
2026-02-03
Open →
Foreign Current
TOTAL VOTING RIGHTS
2026-02-02
Open →
Foreign Current
IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER
2026-02-02
Open →
Foreign Current
ASTRAZENECA BEGINS TRADING ON NYSE
2026-02-02
Open →
Foreign Current
ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC
2026-01-30
Open →
Foreign Current
ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030
2026-01-29
Open →
Foreign Current
ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE
2026-01-20
Open →
Foreign Current
AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON
2026-01-08
Open →
Foreign Current
TOTAL VOTING RIGHTS
2026-01-02
Open →
Foreign Current
DIRECTOR/PDMR SHAREHOLDING
2025-12-22
Open →
Foreign Current
ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC
2025-12-22
Open →
Foreign Current
UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB
2025-12-22
Open →
Foreign Current
DIRECTOR/PDMR SHAREHOLDING
2025-12-19
Open →
Foreign Current
SUBCUTANEOUS SAPHNELO APPROVED IN EU
2025-12-16
Open →
Foreign Current
ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC
2025-12-16
Open →
Foreign Current
HOLDING(S) IN COMPANY
2025-12-04
Open →
Foreign Current
BLOCK LISTING INTERIM REVIEW
2025-12-01
Open →
Foreign Current
TOTAL VOTING RIGHTS
2025-12-01
Open →
Foreign Current
IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER
2025-11-26
Open →
Foreign Current
ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND
2025-11-24
Open →
Foreign Current
KOSELUGO (SELUMETINIB) APPROVED IN THE US
2025-11-20
Open →
Foreign Current
HOLDING(S) IN COMPANY
2025-11-17
Open →
Foreign Current
DIRECTOR/PDMR SHAREHOLDING
2025-11-14
Open →
Foreign Current
DIRECTOR/PDMR SHAREHOLDING
2025-11-10
Open →
Foreign Current
9M AND Q3 2025 RESULTS
2025-11-06
Open →
Foreign Current
RESULT OF GENERAL MEETING
2025-11-03
Open →
Foreign Current
TOTAL VOTING RIGHTS
2025-11-03
Open →
Foreign Current
FORM 6-K
2025-11-03
Open →
Foreign Current
DIRECTOR DECLARATION
2025-10-28
Open →
Foreign Current
KOSELUGO (SELUMETINIB) APPROVED IN THE EU
2025-10-28
Open →
Foreign Current
TEZSPIRE APPROVED IN EU FOR CRSWNP
2025-10-22
Open →
Foreign Current
US FDA APPROVES TEZSPIRE IN CRSWNP
2025-10-20
Open →
Foreign Current
POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO
2025-10-20
Open →
Foreign Current
AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES
2025-10-14
Open →
Foreign Current
BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL
2025-10-07
Open →
Foreign Current
DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02
2025-10-06
Open →
Foreign Current
TOTAL VOTING RIGHTS
2025-10-01
Open →
Foreign Current
ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05
2025-09-29
Open →
Foreign Current
AZN HARMONISES LISTING STRUCTURE
2025-09-29
Open →
Foreign Current
6-K
2025-09-29
Open →
Foreign Current
DIRECTOR/PDMR SHAREHOLDING
2025-09-25
Open →
Foreign Current
KOSELUGO RECOMMENDED FOR EU APPROVAL
2025-09-22
Open →
Foreign Current
TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP
2025-09-22
Open →
Foreign Current
SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC
2025-09-17
Open →
Foreign Current
UPDATE ON RESOLUTE PHASE III TRIAL
2025-09-17
Open →
Foreign Current
TOTAL VOTING RIGHTS
2025-09-02
Open →
Foreign Current
HOLDING(S) IN COMPANY
2025-08-28
Open →
Foreign Current
HOLDING(S) IN COMPANY
2025-08-26
Open →
Foreign Current
HOLDING(S) IN COMPANY
2025-08-21
Open →
Other filings (20)
Insider Transaction
OWNERSHIP DOCUMENT
2026-05-08
Open →
SCHEDULE 13G
xslSCHEDULE_13G_X02/primary_doc.xml
2026-04-28
Open →
25-NSE
xslF25X02/primary_doc.xml
2026-04-08
Open →
3
OWNERSHIP DOCUMENT
2026-03-19
Open →
CERT
NYSE CERTIFICATION
2026-03-04
Open →
8-A12B
FORM 8-A12B
2026-03-03
Open →
424B2
424B2
2026-02-27
Open →
FWP
FWP
2026-02-26
Open →
424B2
424B2
2026-02-25
Open →
IRANNOTICE
IRANNOTICE
2026-02-24
Open →
SCHEDULE 13G/A
xslSCHEDULE_13G_X01/primary_doc.xml
2026-02-06
Open →
SCHEDULE 13D/A
xslSCHEDULE_13D_X01/primary_doc.xml
2026-02-06
Open →
S-8
FORM S-8
2026-02-02
Open →
25
FORM 25
2026-01-30
Open →
CERT
NYSE CERTIFICATION
2026-01-22
Open →
8-A12B
8-A12B
2026-01-22
Open →
CERT
NYSE CERTIFICATION
2026-01-22
Open →
8-A12B
8-A12B
2026-01-22
Open →
25-NSE
xslF25X02/primary_doc.xml
2025-11-14
Open →
144
xsl144X01/primary_doc.xml
2025-11-12
Open →